Enhanced inhibitive effects of combination of rofecoxib and octreotide on the growth of human gastric cancer

International Journal of Cancer - Tập 112 Số 3 - Trang 470-474 - 2004
Chengwei Tang1,2, Liu Chun-lun3, Xuchun Zhou3, Chunhui Wang1
1Department of Gastroenterology, Division of Peptides Related With Human Diseases, Key Laboratory of Biotherapy of Human Diseases, Ministry of Education, West China Hospital, Sichuan University, Chengdu, China
2Fax: +86-28-8542-2351
3Department of Gastroenterology, First Hospital, Chongqing Medical University, Chongqing, China

Tóm tắt

AbstractOur previous studies indicated that cyclooxygenase‐2 inhibitor or octreotide could suppress the proliferation of gastric adenocarcinoma in vitro or in vivo. The present study was aimed to find whether rofecoxib combined with octreotide could enhance the inhibitive effects on the growth of gastric cancer. The effect of rofecoxib or octreotide on proliferation of gastric cancer cell line was determined by 3H‐thymidine ribotide incorporation. The TdT‐mediated dUTP nick end‐labeling assay was used to detect the apopotosis. To determine their synergic antineoplastic effects, the interaction between rofecoxib and octreotide on SGC‐7901 cell was evaluated by the median effect plot. After orthotopical implantion of xenografts of human gastric cancer in stomach, nude mice were given rofecoxib plus octreotide for 8 weeks. Cyclooxygenase‐2 in gastric cancer tissues was measured by immunohistochemistry. Combination of rofecoxib and octreotide presented synergistic effect (combination index < 1) in the majority of responses. The inhibitory rate for xenografts in nude mice was 89.7% in rofecoxib group. Combination of rofecoxib and octreotide enhanced inhibitory rate to 98.8%. The combination greatly increased the apoptotic index (78.20% ± 6.45%) of the xenografts as compared with that of using rofecoxib alone (46.60% ± 3.42%); the difference was very significant (p < 0.001). Rofecoxib could inhibit the activity of cyclooxygenase‐2 in the tissue of gastric adenocarcinomas of nude mice. Our results indicate that combination of rofecoxib and octreotide significantly enhances the antiproliferative effect in gastric adenocarcinoma, which might have potential therapeutic value. © 2004 Wiley‐Liss, Inc.

Từ khóa


Tài liệu tham khảo

Tsuji S, 2001, Cyclooxygenase‐2 upregulation as a perigenetic change in carcinogenesis, J Exp Clin Cancer Res, 20, 117

Ristimaki A, 1997, Expression of cyclooxygenase‐2 in human gastric carcinoma, Cancer Res, 57, 1276

10.1002/1096-9098(200101)76:1<26::AID-JSO1005>3.0.CO;2-A

10.1002/1097-0142(20010515)91:10<1876::AID-CNCR1209>3.0.CO;2-H

10.1002/1529-0131(200002)43:2<370::AID-ANR17>3.0.CO;2-D

Tang C, 2003, Effects of octreotide combined with aspirin on the growth of gastric cancer, Chinese Med J, 116, 378

Liu CL, 2003, The effects of selective cyclooxygenase‐2 inhibitors on the growth of gastric adenocarcinoma, J West China Univ Med Sci, 3, 372

10.1002/(SICI)1097-0215(19990129)80:3<448::AID-IJC19>3.0.CO;2-N

10.3181/00379727-217-44216

10.1002/ijc.2910570422

10.3748/wjg.v9.i9.1904

10.3181/00379727-217-44216

10.1007/BF02976879

Lin CH, 1984, Investigation of SGC‐7901 Cell line established from human gastric carcinoma cells, Chinese Med J, 97, 831

Leonard CE, 1996, Paclitaxel enhance in vitro radiosensitivity of squamous carcinoma cell lines of the head and neck, Cancer Res, 56, 5198

10.1054/bjoc.2001.2027

10.1067/msy.2002.124929

10.1038/sj.bjc.6690486

Saukkonen K, 2001, Expression of cyclooxygenase‐2 in dysplasia of the stomach and in intestinal‐type gastric adenocarcinoma, Clin Cancer Res, 7, 1923

10.1016/S0304-3835(01)00645-0

10.1111/j.1572-0241.1999.876_e.x

Saukkonen K, 2003, Cyclooxygenase‐2 expression and effect of celecoxib in gastric adenomas of trefoil factor 1‐deficient mice, Cancer Res, 63, 3032

10.1054/npep.2001.0848

Ding M, 1999, Asbestos induces activator protein‐1 transactivation in transgenic mice, Cancer Res, 59, 1884

10.1046/j.1462-5822.2003.00324.x

10.1159/000049167

Thông tin
Thông tin xuất bản

International Journal of Cancer

Tập 112 Số 3

470-474

Thông tin tác giả